Polygenic Architecture and Molecular Pathways Underlying Methadone Treatment Response in Opioid Use Disorder: Evidence from an Iranian Cohort
Authors:
- James L. KennedyJKJames L. Kennedy
- Sara Sadat AfjehSASara Sadat Afjeh
- Yuhan HuoYHYuhan Huo
- Clement ZaiCZClement Zai
- Arun K. TiwariATArun K. Tiwari
- Fernanda Dos SantosFSFernanda Dos Santos
- Vanessa GonçalvesVGVanessa Gonçalves
- Mir Davood OmraniMOMir Davood Omrani
Preprint
- 1 October 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Response to methadone maintenance therapy (MMT) varies widely, but its genetic basis remains poorly understood, particularly in non-European populations. We hypothesized that shared polygenic liability across psychiatric and substance use disorders contributes to earlier opioid use disorder (OUD) onset through specific pathways and predicts MMT response. Methods We analyzed 769 Iranian individuals with OUD receiving MMT. After quality control, subsets were used to: (i) test polygenic risk scores (PRS) for psychiatric, substance-use, and antidepressant response traits; and (ii) perform a genome-wide association study (GWAS) for both age of onset and methadone response, integrating locus-specific fine-mapping and MAGMA gene-based and pathway enrichment analyses. Results Higher MDD polygenic risk was associated with reduced odds of methadone treatment response and remained significant in a model jointly including bipolar disorder and schizophrenia PRSs; the latter PRSs were not independently significant. The age-of-onset of OUD GWAS identified a suggestive non-coding locus on chromosome 4 (β=−2.74, P = 1.69×10 − 6 ) and suggestive signals ( P = 1×10 − 5 to 5×10 − 5 ) near GLP1R , MAPK10 , PDE 4 B , TIA 1 and SNRPG. The methadone response GWAS identified suggestive loci in EPHA5 (OR = 1.81, P = 9.9×10 − 6 ) and HOMER1 (OR = 0.54, P = 1.6×10 − 5 ). Pathway analysis implicated branched-chain amino acid and fatty acid metabolism in age at onset (FDR<0.05), and TGF-β and JAK–STAT signaling in methadone response ( P =9.9×10⁻⁷–1.1×10⁻³; FDR<0.05). Conclusions Distinct but convergent polygenic and biological mechanisms shape opioid-use onset and methadone response, implicating psychiatric liability, metabolic regulation, and neuroimmune signaling as candidate mechanisms of clinical heterogeneity in OUD.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Antidepressant Switching as a Proxy Phenotype for Drug Nonresponse: Investigating Clinical, Demographic, and Genetic CharacteristicsBiological Psychiatry Global Open Science, 2025
- Once-Weekly Semaglutide in Adults With Alcohol Use DisorderJAMA Psychiatry, 2025
- Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use DisorderJAMA Network Open, 2024
- Managing differential performance of polygenic risk scores across groups: Real-world experience of the eMERGE NetworkThe American Journal of Human Genetics, 2024
- Identification of TIA1 mRNA targets during human neuronal developmentMolecular Biology Reports, 2021
- When to adjust alpha during multiple testing: a consideration of disjunction, conjunction, and individual testingSynthese, 2021
- Genetic Perturbation of TIA1 Reveals a Physiological Role in Fear MemoryCell Reports, 2019
- Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorderPsychopharmacology, 2018
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Ephrin‐A5 regulates the formation of the ascending midbrain dopaminergic pathwaysDevelopmental Neurobiology, 2008